Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pulmatrix Inc    PULM

 SummaryQuotesChartsNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
2.76(c) 2.6772(c) 2.89(c) 2.83(c) 2.76(c) Last
286 424 323 411 1 373 955 320 078 233 387 Volume
-3.50% -3.00% +7.95% -2.08% -2.47% Change
More quotes
Company
Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs.It designs and develops inhaled therapeutic... 
More about the company
Latest news on PULMATRIX INC
03/30 PULMATRIX : Receives European Patent for its Inhaled Drug Delivery Technology
03/27 PULMATRIX : Adds Two Top Fungal Infection Experts to its Scientific Advisory Boa..
03/27 5 TOP NASDAQ BIOTECH STOCKS : Nektar Therapeutics Gained 44.71 Percent
03/24 PULMATRIX : secures EU patent for dry powder delivery tech
03/23 PULMATRIX : PULM) Descends After Wednesday Rise
03/22 PULMATRIX INC : Today's Research Reports on Stocks to Watch: Pulmatrix and Aevi ..
03/22 MIDWEEK BIOTECH MOVERS : Pain Therapeutics, Inc. (NASDAQ:PTIE) and Pulmatrix, In..
03/21 PULMATRIX : Receives European Patent for its Inhaled Drug Delivery Technology
03/17 PULMATRIX, INC. (NASDAQ : PULM) Files An 8-K Entry into a Material Definitive Ag..
03/17 PULMATRIX, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
More news
Sector news : Bio Therapeutic Drugs
10:30a REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
07:45aDJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/11TherapeuticsMD Inc : Today's Research Reports on Biotech Stocks to Watch: The.. 
04/09Big Booming Breakouts
1
04/04Big Booming Breakouts  
04/02Booming Breakouts  
03/31$PULM New High: 0.02. Next resistance 3.75 from 3/27/2017 #tradeideas 
More tweets
Qtime:7
News from SeekingAlpha
03/29 Pulmatrix perks up 8% on rumored Mylan interest
03/24 Matinas BioPharma Has A Weak Drug Pipeline And Investors With Fraudulent Hist..
03/22 PREMARKET GAINERS AS OF 9 : 05 am
03/21 After Hours Gainers / Losers
03/21 Midday Gainers / Losers
Advertisement
Chart PULMATRIX INC
Duration : Period :
Pulmatrix Inc Technical Analysis Chart | PULM | US74584P1030 | 4-Traders
Full-screen chart
Technical analysis trends PULMATRIX INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Managers
NameTitle
Robert W. Clarke President, Chief Executive Officer & Director
Mark T. Iwicki Chairman
William E. Duke Chief Financial Officer, Treasurer & Secretary
David L. Hava Chief Scientific Officer
Terrance G. McGuire Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PULMATRIX INC379.66%50
AMGEN, INC.11.29%119 744
CELGENE CORPORATION7.10%96 445
GILEAD SCIENCES, INC.-4.23%89 650
REGENERON PHARMACEUTIC..-0.13%38 968
ACTELION LTD26.44%29 633
More Results